#USA #Tampa #Chronic Pain #PainTEQ #TRAQTION

PainTEQ Launches TRAQTION Study to Revolutionize Pain Management

PainTEQ, a frontrunner in minimally invasive solutions for chronic pain, announced a significant milestone—enrolling the first patient in the TRAQTION Study. This multicenter clinical trial aims to evaluate the outcomes associated with the innovative posterior sacroiliac joint procedures that utilize the advanced cortical-piercing TRAQ™ allograft.

The first patient was enrolled by Dr. Kevin Henry from the Pain Institute of Southern Arizona, located in Tucson, Arizona. The initial procedure was carried out by Dr. Patrick Buchanan of Spanish Hills Interventional Pain Specialists in Camarillo, California. These events represent not just a step forward in the study but also a leap toward advancing treatment options for patients experiencing chronic pain.

The TRAQTION Study plans to enroll up to 100 participants from as many as 10 different sites across the United States. Over a span of 24 months, the researchers will meticulously track a variety of outcomes, including patient-reported results, safety, and healthcare utilization rates connected to the posterior sacroiliac joint procedures using the TRAQ™ technology.

TRAQ™ is ingeniously designed to navigate the sacroiliac joint effectively, employing a trajectory that penetrates both the sacrum and ilium. This method enhances upon existing techniques by adding an essential step that promotes cortical engagement, thereby potentially improving the therapeutic outcomes for patients undergoing these procedures.

Dr. Eric Cornidez, the Chief Medical Officer at the Pain Institute of Southern Arizona, highlighted the importance of this study, stating, "The enrollment of the first patient signifies a crucial milestone in evolving posterior sacroiliac joint procedures. I am excited to be part of a study that will contribute valuable insights into this innovative approach."

Echoing Dr. Cornidez, Dr. Lalit Venkatesan, Senior Vice President of Clinical Research at PainTEQ, remarked on the study's design: "The cortical engagement method represents a significant advancement for PainTEQ, and the TRAQTION Study is structured to evaluate it rigorously. Two years of follow-up with a diverse group of participants will allow us to gain critical insights into durability, safety, and patient experiences—exactly the evidence that clinicians need to tailor these procedures for their patients."

The commencement of the TRAQTION Study not only marks an important step in clinical research but also exemplifies PainTEQ's steadfast commitment to generating solid clinical evidence that fosters deeper understanding and enhances patient outcomes following posterior sacroiliac joint procedures.

The study promises to provide much-needed data to inform both clinicians and patients about the effectiveness of these advanced treatments for chronic pain. More details regarding the TRAQTION Study can be located at ClinicalTrials.gov (NCT07547215).

About PainTEQ

Founded in 2013 and based in Tampa, Florida, PainTEQ has set the bar in minimally invasive solutions for chronic pain management. The company is dedicated to innovating advanced technologies, compiling clinical evidence, and facilitating physician education aimed at improving the quality of patient care. Through its ongoing commitment to research and physician training, PainTEQ remains steadfast in its mission to broaden treatment alternatives for individuals suffering from chronic pain.

Conclusion

The initiation of the TRAQTION Study represents a vital expansion in clinical research aimed at chronic pain alleviation. PainTEQ’s investment in this innovative study underscores its commitment to improving treatment pathways, thereby enhancing the quality of life for countless patients facing chronic pain challenges.